| ●Editorial | Yamada H | 194-5 | Full text | |
| ●Perspectives toward global health: Life-saving portfolios | ||||
| Round table discussion: The 2nd round table discussion on development of new medicines for neglected tropical diseases: From bench to bed, achievements and challenges Part 1 Partnerships, treatments and NTDs: 2005 to 2018, 13 years of change Part 2 Progress and challenges of development towards global health: Proposals for revolution |
Croft SL，Yamada H， Kita K，et al． （Dictation and translation by：Hirabayashi F． Organized by：Kurihara C，Saio T） |
197-235 | Abstract | |
| “Magic bullet” from Japan: Gift from nature and unexpected development | Kita K | 237-43 | Abstract | |
| The aftermath of the priority medicines project: On its remaining problems | Saio T | 245-52 | Abstract | |
| Insights on pharmaceutical medicine: From promotional marketing to innovation for global health | Kurihara C，Imamura K | 253-61 | Abstract | |
| ●Front line of academia-initiated product development / Regulatory considerations in Japan and the US | ||||
| Prospect for self-sustaining ARO (Academic Research Organization) －In view of establishing an R&D eco-cycle | Fukushima M | 263-86 | Abstract | |
| The accomplishment of Japanese TR Centers in 2017 and future prospects | Nishimura H，Kurita K， Kikuchi T，et al． | 287-301 | Abstract | |
| Comparing GCP requirements for serious adverse event reporting in the US, EU, and Japan －The impact of GCP renovation on the Japanese Clinical Trials Act 2017－ |
Ohtsu H，Shinano H， Matsuoka K，et al． | 303-20 | Abstract | |
| The generation and development of the system of Investigational New Drug
in the US －Its regulatory scope | Akimoto N | 321-34 | Abstract | |
| Compensation for clinical trial-related injury in sponsor-initiated or investigator-initiated trials of drugs, medical devices, and regenerative medical products: Commonalities and differences in the applicability of JPILA guidelines |
Kurihara C，Koike R， Okada K，et al． | 335-83 | Abstract | |
| ●Forum | ||||
| A fair shot for affordable pneumonia vaccine: Why overcoming patent barriers to PCV13 is vital for saving children’s lives? | Médecins Sans Frontières（MSF） | 385-8 | Full text | |
| Introducing ICPM 2018: The Future of Medicines Development | ICPM 2018 Organizing Committee （Imamura K，Nishiuma S， Matsuyama K，Iwamoto K） |
389-94 | Full text | |
| ●Instructions for authors［Japanese］ & ［English］ | 395-403 | Full text | ||
| ●Editor's note | Fukushima M | 405 | Full text | |
| ［Electronic publications only］ | ||||
| ●Forum | ||||
| A fair shot for affordable pneumonia vaccine: Why overcoming patent barriers to PCV13 is vital for saving children’s lives? |
Médecins Sans Frontières（MSF） | 407-10 W45-W48 |
Full text | |
| ●Perspectives toward global health: Life-saving portfolios | ||||
| Round table discussion：The 2nd round table discussion on development of new medicines for neglected tropical diseases: From bench to bed, achievements and challenges －Partnerships, treatments and NTDs: 2005 to 2018, 13 years of change－ |
Croft SL，Yamada H， Kita K，et al． （Dictation by：Hirabayashi F． Organized by：Kurihara C，Saio T） |
411-29 W55-W73 |
Full text | |